DAXOR CORPORATION TO EXHIBIT AT THE SOCIETY FOR CRITICAL CARE MEDICINE 50TH CONGRESS VIRTUAL EVENT
January 26 2021 - 8:30AM
Daxor Corporation (NYSE MKT: DXR), the global leader in blood
volume measurement technology (organized as an investment company
with fully owned innovative medical instrumentation and
biotechnology operations), announces today that it will be
exhibiting at the Society for Critical Care Medicine (SCCM) 50th
Congress Virtual Event, January 31st through February 12th, 2021.
Research from the University of Hawaii - John A. Burns School of
Medicine relating to the use of Daxor’s BVA-100 (Blood Volume
Analyzer) diagnostic blood test in critical care use is scheduled
to be presented.
“Peer-reviewed studies including a randomized
control trial have demonstrated that, compared to standard care,
actionable BVA-100 information changed surgical intensive care unit
(SICU) fluid and red blood cell interventions in 44% of cases,
while reducing patient mortality by 66%, while also reducing
patients’ length of stay and days on a ventilator,” said Michael
Feldschuh, CEO and President of Daxor Corporation. “We look forward
to sharing with leaders new data on how precise, individualized
fluid management can lead to better patient outcomes.”
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the first diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. The BVA technology enhances hospital performance metrics in
a broad range of surgical and medical conditions, including heart
failure and critical care, by informing treatment strategies,
resulting in significantly improved multiple measures of patient
outcomes. Daxor's mission is to advance healthcare by enabling
optimal fluid management with blood volume analysis. Daxor’s vision
is optimal blood volume for all. For more information, please visit
our website at Daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Apr 2023 to Apr 2024